MICHAEL WOOD, MBA

Mike is a biotech entrepreneur with a successful track record of fundraising, building teams, business development, and scaling company operations while transitioning from preclinical to clinical development.

He previously founded OncoMyx Therapeutics, a cancer therapeutics company, served as COO/CFO, raised $75 million, recruited key executives at the Board, management and advisory levels, and scaled operations to 25 employees while transitioning OncoMyx into a clinical-stage company. In addition, he joined Crinetics Pharmaceuticals (NASDAQ: CRNX), an endocrine therapeutics company, shortly after inception, served as Vice President of Corporate Development & Operations, raised its initial $40 million series A, helped build the team, and scaled operations to 50 employees while transitioning Crinetics into a clinical-stage company. At Orexigen Therapeutics, an obesity therapeutics company, he executed a $1 billion co-development and co-commercialization deal with Takeda. At Abbvie, he launched a blockbuster ($1 billion) drug and earned the company’s top 1% sales award as a pharmaceutical sales representative, launched another blockbuster drug on the marketing team, and worked on a variety of deals on the business development team. He trained in investment banking at Morgan Stanley, management consulting at Tenet Healthcare, and as a scientist at the Salk Institute, UC Berkeley/HHMI and UC San Francisco.

Mike earned his BS in molecular and cell biology, summa cum laude and phi beta kappa, from UC Berkeley, and he earned his MBA in finance, strategy and entrepreneurship from the University of Chicago. While at Cal, he was a member of the university’s rowing team for four years, and in his final year his boat won the national championship and set a world record.